Raymond James & Associates Takes $609,000 Position in 10x Genomics, Inc. (NASDAQ:TXG)

Raymond James & Associates purchased a new position in 10x Genomics, Inc. (NASDAQ:TXG) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,903 shares of the company’s stock, valued at approximately $609,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TXG. Harvest Fund Management Co. Ltd purchased a new stake in 10x Genomics during the 1st quarter valued at $39,000. Atlas Capital Advisors LLC lifted its holdings in 10x Genomics by 41.7% in the second quarter. Atlas Capital Advisors LLC now owns 935 shares of the company’s stock valued at $42,000 after acquiring an additional 275 shares during the period. Natixis purchased a new position in 10x Genomics in the fourth quarter worth about $74,000. Capital Impact Advisors LLC grew its stake in shares of 10x Genomics by 26.4% during the 4th quarter. Capital Impact Advisors LLC now owns 2,776 shares of the company’s stock valued at $101,000 after purchasing an additional 580 shares during the period. Finally, Counterpoint Mutual Funds LLC purchased a new stake in shares of 10x Genomics during the 2nd quarter valued at about $104,000. 79.16% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Serge Saxonov sold 3,757 shares of 10x Genomics stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $45.78, for a total value of $171,995.46. Following the transaction, the chief executive officer now owns 864,093 shares of the company’s stock, valued at approximately $39,558,177.54. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CEO Serge Saxonov sold 3,757 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $45.78, for a total transaction of $171,995.46. Following the sale, the chief executive officer now owns 864,093 shares in the company, valued at $39,558,177.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Justin J. Mcanear sold 1,678 shares of 10x Genomics stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $45.78, for a total transaction of $76,818.84. Following the completion of the sale, the chief financial officer now owns 98,784 shares of the company’s stock, valued at $4,522,331.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 19,155 shares of company stock worth $892,624. 10.65% of the stock is currently owned by corporate insiders.

10x Genomics Stock Performance

Shares of NASDAQ:TXG opened at $39.02 on Wednesday. The firm’s 50 day simple moving average is $42.65 and its 200-day simple moving average is $50.37. The firm has a market cap of $4.58 billion, a PE ratio of -26.19 and a beta of 1.84. 10x Genomics, Inc. has a one year low of $30.19 and a one year high of $63.57.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on TXG shares. Canaccord Genuity Group restated a “buy” rating and issued a $70.00 price objective on shares of 10x Genomics in a research note on Tuesday, September 19th. Morgan Stanley reissued an “overweight” rating and issued a $65.00 target price on shares of 10x Genomics in a report on Monday, August 7th. Citigroup upped their price target on shares of 10x Genomics from $65.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. Finally, Barclays decreased their price objective on shares of 10x Genomics from $66.00 to $47.00 and set an “overweight” rating on the stock in a research report on Friday, September 29th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $60.78.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.